Company Profile

Industry Sector: Medical Devices

Company Overview: customKYnetics, Inc. is an early stage research and development company that focuses on development of rehabilitation engineering products for use by individuals with neuromotor or other musculoskeletal disorders. customKYnetics’ core competencies include control and delivery of neuromuscular electrical stimulation, instrumentation, and embedded systems.

Target Market(s): Major Rehabilitation Hospitals & Physical Therapy providers serving the spinal cord injury, stroke, and sports medicine populations.

Key Value Drivers

Technology*
- ACLerator™ system – quadriceps strengthening for patients with Osteoarthritis, or for those undergoing rehabilitation following ACL or TKA surgery.
- KaiSTIM™ adaptive stimulation control technology.
- CK200 high output NMES unit (patent pending)

Competitive Advantage: ACLerator system is based on a proven technique for post-surgical rehabilitation that provides improvements in 6-weeks that are normally not seen for 24-months. System features include: 1) knee stabilization to protect the post-surgical joint; 2) dose response of electrical stimulation; 3) high-output NMES unit; and 4) turn-key operation using KaiSTIM stimulation control.

Plan & Strategy: Commencing sales to initial market (professional/collegiate athletic teams). Grow into mass market therapy clinics via strategic partnership.

*Technology funded by the NCMRR/NICHD and being commercialized under the NIH-CAP

Management

Leadership:
- Eric Hartman, President
- John Alton, Director of Engineering Operations
- Mandy Hensley, Director of Regulatory Operations

Board of Directors / Owners:
- Eric Hartman, President, customKYnetics, Inc.
- James Abbas, Associate Professor, Arizona State University
- JoAnne Resig, Biomedical Engineer

Product Pipeline

ACLerator is one of five (5) products slated for market release within 12-18 months. customKYnetics received FDA marketing approval for its first product in Jan’09 and is actively working to build manufacturing infrastructure.

customKYnetics will submit an FDA 510(k) application in June’09 that, if approved, will permit marketing of four other products, including the ACLerator.

Other products and support technologies are at various stages of development. Improved versions of products intended for initial release are also in development.